title: [Prevalence of mood disorders in Parkinson's disease patients treated with subthalamic nucleus deep brain stimulation].
abstract: Subthalamic nucleus deep brain stimulation (STN-DBS) is a recognized treatment for advanced and severe forms of Parkinson's Disease. The procedure improves motor signs and often allows a reduction of the medication. The impact of the procedure on cognitive and neuropsychiatric signs of the disease is more debated and there is an international consensus for the need of a multidisciplinary evaluation of patients undergoing such programs, including a neuropsychiatric assessment. We present a review of the literature as well as the experience at our centre focused on the short and long term outcome on mood following STN-DBS.
authors.affiliation: Faculté de biologie et médecine, Université de Lausanne, Rue du Bugnon 21, 1015 Lausanne. Hannah.Maes@unil.ch
authors.forename: H
authors.initials: H
authors.lastname: Maes
authors.forename: F
authors.initials: F
authors.lastname: Vingerhoets
authors.forename: A
authors.initials: A
authors.lastname: Berney
mesh_terms: D000368:Aged; D000928:Antidepressive Agents / Q000627:therapeutic use; D046690:Deep Brain Stimulation / Q000009:adverse effects* / Q000379:methods; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D019964:Mood Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology* / Q000209:etiology*; D010300:Parkinson Disease / Q000175:diagnosis / Q000523:psychology* / Q000628:therapy*; D015995:Prevalence; D011446:Prospective Studies; D011569:Psychiatric Status Rating Scales; D012720:Severity of Illness Index; D020531:Subthalamic Nucleus / Q000601:surgery*; D013557:Switzerland / Q000453:epidemiology; D016896:Treatment Outcome
chemical_list: D000928:Antidepressive Agents